Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.

Sponsor
Ottawa Hospital Research Institute
Study ID
NCT05153200
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this phase 4 pilot study is to assess 1-year recruitment, and 6-month retention rates for participants with rheumatoid arthritis (RA) recruited to this study. Secondarily, we aim to study the difference in multifaceted pain scoring and Musculoskeletal Ultrasound (MSK-US)-detected synovitis between those treated with Upadacitinib vs Adalimumab.

Key Dates

Start date
Jan 31, 2022
Status verified
Nov 2021
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Upadacitinib(Rinvoq)
    Upadacitinib(Rinvoq) 15 mg po daily
  • Active Comparator: Adalimumab(Idacio)

Primary Outcome Measure

Recruitment Rate [ Time Frame: 1 year ]

Central Contacts

Related Studies